Announcement on Cefuroxime Axetil for Suspension Passing Consistency Evaluation
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Cefuroxime Axetil for Suspension Passing Consistency Evaluation
Filed with SSE · · 2 pages · Chinese
On 6ix: 6ix.com/news/announcement-on-cefuroxime-axetil-for-suspension-passing-consistency-evaluation
Release
Shandong Lukang Pharmaceutical Co., Ltd. on 6ix
Earlier from Shandong Lukang Pharmaceutical
- Indicative Announcement on Reply Update to Letter of Review and Inquiry on Application Documents for Shares Issuance to Specific Objects
- Semi-annual Earnings Preannouncement for 2025
- Announcement on Obtaining Drug Registration Certificate and Approval Notice for Chemical Active Pharmaceutical Ingredient Market Application
- Announcement on Reply to the Review Inquiry Letter of Application Documents for Issuance of Shares to Specific Objects by Shandong Lukang Pharmaceutical Co., Ltd. (Revised Draft)
- Announcement on Implementation of Dividend Distribution for 2024
Later from Shandong Lukang Pharmaceutical
- Announcement on Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of CIGB-814 for Injection
- Announcement on SSE Approval of Application for Issuance of Shares to Specific Objects
- Announcement on Canceling the Board of Supervisors and Amending the Articles of Association, and Revising, Formulating and Abolishing Some Goverance Systems
- Announcement on the Holding Subsidiary Obtaining the Supplementary Application Approval Notice for Methocarbamol Injection and Becoming the Marketing Authorization Holder of the Drug
- Announcement on Convening the 2025 Semi-annual Performance Briefing
Follow Shandong Lukang Pharmaceutical into a list and get an email when it puts out news.
Follow Shandong Lukang Pharmaceutical